Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments by Julie Winstone et al.
RESEARCH Open Access
Review and comparison of clinical evidence
submitted to support European Medicines Agency
market authorization of orphan-designated
oncological treatments
Julie Winstone1, Shkun Chadda1*, Stephen Ralston1 and Peter Sajosi2
Abstract
Background: Clinical trials for treatments indicated for orphan diseases may be limited due to the low prevalence
of such diseases; this can result in implications for both regulatory and health economic perspectives. This study
assessed the pivotal clinical evidence packages submitted to support applications for European Medicines Agency
(EMA) marketing authorizations for treatments for orphan conditions, in relation to the size of the eligible patient
population.
Methods: Approved treatments for EMA-designated orphan conditions (defined as life-threatening or chronically
debilitating conditions that affect ≤5/10,000 people) were identified from the EMA web site. All treatments
reviewed were included in anatomical therapeutic chemical (ATC) category L (antineoplastic and
immunomodulating drugs): this category was selected because it is the largest ATC category, containing almost
50 % of all approved orphan-designated products. Treatments were reviewed if they had been approved within the
past 7 years and had been evaluated in a controlled trial using at least one survival-based clinical endpoint.
Treatments were compared in terms of patient-years (accumulated duration of follow-up), the number of patients
in the pivotal trials and disease prevalence.
Results: As of 1 February 2014, 68 treatments had been approved for orphan-designated conditions, of which 30
belonged to ATC category L and 14 met all inclusion criteria. The number of patients in the pivotal trials ranged
from 162 to 846 (median 485). In terms of patient-years, the longest duration of follow-up was seen in the pivotal
trial of mifamurtide in osteosarcoma, which had 4068 patient-years; excluding this trial, follow-up ranged from 308
to 2906 patient-years (median 1796 years). Osteosarcoma had the second smallest eligible patient population
(0.5/10,000 persons) of the reviewed treatments.
Conclusions: Clinical trials of orphan treatments are often limited by low patient numbers and inadequate
follow-up. Pooling of expertise in single centres and the establishment of rare disease reference networks and
patient registries may facilitate appropriate trial design for orphan-designated treatments. This analysis found that
the pivotal clinical trial for mifamurtide in osteosarcoma had the largest number of patient-years of follow-up,
despite a small eligible patient population, showing that it is possible to conduct studies with an adequate patient
population size and duration of follow-up in patient-years, and a comparative design with clinical, survival-based,
endpoints.
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Background
Although definitions of orphan diseases vary, it is gener-
ally accepted in most countries that such disorders affect
between 1 and 8 individuals per 10,000. Within the
European Union (EU), orphan conditions are defined by
the European Medicines Agency (EMA) as life-
threatening or chronically debilitating conditions that
affect no more than 5 in 10,000 people (equivalent to
approximately 250,000 or fewer people for each condi-
tion) in the EU [1–3].
There are difficulties in balancing the urgent need for
drugs to treat rare diseases with the requirements for
guaranteed quality, efficacy and safety and, when neces-
sary, making comparisons with existing therapies. Reli-
able methods of evaluating drugs in small numbers of
patients are problematic, adding to difficulties in produ-
cing high-quality dossiers, despite incentives for pharma-
ceutical companies to develop such products and the
use of less stringent criteria for trials of drugs with des-
ignated orphan indications [4]. These problems are evi-
dent even when the efficacy of a potential treatment is
well established in other indications [1]. For these rea-
sons, clinical data submitted to support an application
for marketing authorization of treatments for orphan
conditions may often be less robust than is the case for
treatments for non-orphan common conditions. In a
study in 2006, for example, 10 of 18 (55 %) approved
orphan-designated treatments were authorized ‘under
exceptional circumstances’, indicating that the clinical
dossiers were incomplete and that further studies would
be needed to maintain the marketing authorization [4].
Overall, only nine of the approved treatments (50 %)
were supported by RCT data: five were supported only
by uncontrolled Phase II studies, two by uncontrolled
open-label studies, and one by a literature analysis alone.
Other limitations of the submitted data included the use
of surrogate endpoints and inadequate durations of
follow-up in relation to the natural history of the disease.
A subsequent study by the same authors suggested that
this situation persisted throughout the first decade after
implementation of orphan drug legislation in the EU [5].
The limitations of the clinical evidence submitted to
support marketing authorizations for orphan treatments
have a number of implications. Poorly designed pivotal
trials may contribute to a low rate of success for such
applications both in the EU [4, 6] and the USA [7]. Fur-
thermore, limited pivotal trial data, together with the
high cost of many orphan treatments, may create diffi-
culties in terms of reimbursement and market access
[1, 8, 9]. As the number of orphan-designated treat-
ments entering clinical practice increases, it is possible
that the data supporting an application for marketing
authorization may increase. Indeed, it has recently been
suggested that submission of objective data on the natural
history of a disease and the potential impact of the pro-
posed new treatment could form an additional criterion
for decision-making on market access and reimbursement
policies [10]. A further consideration is that marketing au-
thorizations based on limited clinical data could poten-
tially expose the patient to increased risk of adverse
events or lack of efficacy, compared with non-orphan
treatments [11]. In view of these issues, the present
study was performed to evaluate the pivotal clinical
evidence packages presented in the European Public
Assessment Report for orphan-designated treatments
with an EMA marketing authorization.
Methods
This study reviewed the clinical evidence packages for
treatments approved by the EMA. All treatments in-
cluded in the review belong to anatomical therapeutic
chemical (ATC) category L (antineoplastic and immuno-
modulating agents); this category was chosen because it
is the largest ATC category, containing almost 50 % of
all orphan-designated treatments that have received
marketing authorization from the EMA. Treatments
were eligible for inclusion in the review if they had been
approved after 31 December 2006 and had been evalu-
ated in a comparative trial using at least one survival-
based clinical endpoint as opposed to short-term surro-
gate endpoints. The time limit was imposed to ensure
that all included treatments had been evaluated by the
EMA using similar criteria: it is possible that older treat-
ments might have been evaluated using less stringent
criteria than recently approved treatments. Similarly, the
requirement for comparative studies using survival-
based endpoints was imposed because such studies can
be considered the ‘gold standard’ for clinical trials in on-
cology and are recommended in United States Food and
Drug Administration guidance [12]. Eligible treatments
were compared in terms of the number of patients in-
cluded in pivotal (‘main’) clinical trials submitted to sup-
port the application for marketing authorization, the
cumulative duration of follow-up in the pivotal trials,
expressed in patient-years, and the prevalence of the
orphan condition. The number of patient-years of
follow-up was calculated by multiplying the total num-
ber of patients in each study (across all treatment arms)
by the study duration; where the study duration was
not reported explicitly, Kaplan-Meier curves or data ta-
bles were used to estimate the duration of follow-up.
Prevalence data for each orphan-designated condition
were obtained from the relevant EMA Committee for
Orphan Products public summary of opinion [3]: where
these data were provided as the number of affected pa-
tients in the EU, this was converted to the rate per
10,000 based on the EU population at the time of or-
phan designation.
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In addition to patient numbers and duration of follow-
up, the quality of the pivotal trials for all orphan prod-
ucts approved by the EMA since 31 December 2006 was
assessed by means of the Jadad scoring system [13]. In
this system, a maximum of two points each are given for
appropriate randomization and blinding, and a further
point is given if all patients are adequately accounted
for; thus, the maximum possible Jadad score is 5.
Results
As of 1 February 2014, 68 treatments with 87 indications
had received an EMA marketing authorization for
orphan-designated conditions. The prevalence of the or-
phan indications varied markedly, from 0.00125/10,000
persons for N-acetylglutamate synthetase deficiency
to <4.5/10,000 persons for adrenal insufficiency.
Of the 68 orphan treatments, 30 belonged to ATC cat-
egory L (antineoplastic and immunomodulating agents);
of these, 21 had received a normal marketing authorization,
four had received a conditional authorization, and five
were authorized under exceptional circumstances. The 30
treatments were approved for 41 orphan indications: 19
were approved for a single indication and 11 were ap-
proved for two indications. Four treatments were excluded
from the analysis because only literature reports, rather
than clinical trial data, were provided as pivotal study evi-
dence. For the remaining 37 indications, 52 % of the piv-
otal studies were Phase III trials, and randomized clinical
trial (RCT) data were provided in 57 %. Overall, 73 % of
studies had at least one clinical endpoint, but only seven
studies (15 %) included a survival-based clinical primary
endpoint.
A total of 14 products met all the inclusion criteria,
having been authorized within the previous 7 years and
supported by comparative trial data with at least one
survival-based clinical endpoint (Table 1). The median
number of patients included in the pivotal trials of these
treatments was 485, and the number of patients ranged
from 162 in a trial of temsirolimus in mantle cell lymph-
oma to 846 in a trial of nilotinib in chronic myelogenous
leukaemia (Fig. 1a). The cumulative duration of follow-
up, expressed in patient-years, also varied widely
(Fig. 1b), from 308 patient-years in the temsirolimus trial
in mantle cell lymphoma to 4068 patient-years in a trial
of mifamurtide in osteosarcoma [14]. Follow-up in the
latter trial appeared to be particularly extensive: when
this trial was excluded from the analysis, the duration of
follow-up ranged from 308 to 2906 patient-years, with a
Table 1 Orphan-designated treatments meeting criteria for review
Generic name Proprietary name Orphan condition Prevalence of orphan condition
Histamine dichloride Ceplene Adult acute myeloid leukaemia in first remission 0.7/10,000
Decitabine Dacogen Adult acute myeloid leukaemia <1/10,000
Pirfenidone Esbriet Adult mild to moderate idiopathic pulmonary fibrosis ≤3/10,000
5-aminolevulinic
acid
Gliolan Visualization of malignant tissue during surgery for
malignant glioma in adults
1/10,000
Pomalidomide Imnovid Multiple myeloma 2.2/10,000
Ruxolitinib Jakavi Splenomegaly or symptoms in adult patients with
primary myelofibrosis
0.5/10,000
Mifamurtide Mepact Osteosarcoma 0.5/10,000
Sorafenib Nexavar Hepatocellular carcinoma; renal cell carcinoma Hepatocellular carcinoma: 1/10,000;
renal cell carcinoma: not reported
Lenalidomide Revlimid Multiple myeloma 1.3/10,000
Nilotinib Tasigna Adult patients with newly diagnosed Philadelphia-
chromosome-positive chronic myelogenous leukaemia
46,000 persons in EU (calculated as 1.0/10,000
based on EU population 457.7 million)
Adult patients with Philadelphia-chromosome-positive
chronic myelogenous leukaemia with resistance or
intolerance to prior therapy including imatinib
Thalidomide Thalidomide
Celgene
Untreated multiple myeloma in adults aged >
65 years or ineligible for high-dose chemotherapy
1.2/10,000
Temsirolimus Torisel Renal cell carcinoma; adult patients with relapsed
and/or refractory mantle cell lymphoma
Renal cell carcinoma: 3.5/10,000; refractory
mantle cell lymphoma: 0.4/10,000
Azacitidine Vidaza Adults not eligible for haematopoietic transplant with
myelodysplastic syndromes, chronic myelogenous
leukaemia, and acute myeloid leukaemia
1.1–3/10,000
Trabectedin Yondelis Treatment of patients with advanced soft tissue
sarcoma
23,000 persons in EU (calculated as 0.6/10,000
based on EU population 377 million)
EU European Union
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median of 1796 patient-years. A comparison of the dur-
ation of follow-up with the reported prevalence of the
orphan condition (Fig. 2) showed that the osteosarcoma
indication for mifamurtide, at 0.5/10,000, had the second
smallest eligible patient population of the reviewed treat-
ments: only the mantle cell lymphoma indication for
temsirolimus had a lower prevalence (0.4/10,000).
In general, the quality of the pivotal trials, as assessed
by Jadad scores, was moderate. The mean (±SD) Jadad
score was 2.6 ± 1.8, and the median score was 3 (range
0–5). Of the 116 trials assessed, only 74 (63.8 %) were
randomized and 55 (47.4 %) were blinded; the numbers
of trials considered adequately randomized or blinded
were 41 (35.3 %) and 45 (38.8 %), respectively. The trial
with the most extensive follow-up, the mifamurtide
osteosarcoma trial, had an overall Jadad score of 3,
reflecting its randomized open-label design.
Discussion
The results of this study show that pivotal trials of treat-
ments for orphan conditions are often limited by a
number of methodological factors, including a lack of
Fig. 1 Number of patients (a) and cumulative duration of follow-up (b) in included studies. All treatments belonged to ATC class L (antineoplastic
and immunomodulatory agents). For inclusion in the review, treatments were required to have received EMA authorization for orphan-
designated conditions within the previous 7 years, and to be supported by comparative trials with at least one survival-based clinical endpoint.
Duration of follow-up was estimated by multiplying the total number of patients in each study by the study duration, or from Kaplan-Meier
curves if these data were not available. MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; OC, ovarian cancer;
RCC, renal cell carcinoma; STS, soft tissue sarcoma
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randomization or blinding, low patient numbers (median
485) and limited follow-up (median 1796 patient-years). It
is important to emphasize however that, notwithstanding
these limitations, all the treatments were approved by the
EMA.
These findings are consistent with previous studies
that have found significant limitations in the design of
clinical trials for orphan treatments both in the EU [4, 5]
and the USA [7]. Factors contributing to these limita-
tions include a lack of pooling of manpower and re-
sources for rare diseases. The lack of specialist centres
with multidisciplinary teams with expertise in particular
rare diseases can result in a lack of data to understand
the natural history of the disease or to inform clinical
and transitional research. This situation may be im-
proved by the establishment of sustainable patient regis-
tries for specific rare diseases and European reference
networks of patient registries [15], which should facili-
tate active and prospective monitoring of clinical inter-
ventions for rare diseases [16].
Orphan drug policies may be unsatisfactory from sev-
eral viewpoints. For example, access to orphan drugs
may be restricted in patients with some rare diseases,
and funds may not be made available to pay for therap-
ies when they have been developed [17]. Against this
background, the low prevalence of orphan disorders (<5/
10,000 population in the EU) remains a major problem
in the design of pivotal clinical trials [4]. Even when the
prevalence is relatively high compared with other orphan
conditions (as is the case for many of the products in-
cluded in this review), trials may still be conducted in an
inadequate number of patients. A study by Joppi et al.,
for example, found that pivotal trials in treatments for
Fabry disease included only 41 and 56 patients out of a
potential patient population of 10,000 in Europe [4]. By
contrast, the present study found evidence that a small
patient population need not necessarily be a barrier to
adequate patient recruitment. The pivotal study of mifa-
murtide in osteosarcoma had the largest number of
patient-years of follow-up and the fourth largest number
of patients of all reviewed treatments, despite the low
prevalence of osteosarcoma (0.5/10,000). Indeed, it is
noteworthy that only one indication, for temsirolimus in
mantle cell lymphoma, had a smaller eligible patient
population (Fig. 2); this pivotal trial also had the smallest
number of patients and the shortest cumulative follow-
up. Three pivotal trials, for pirfenidone in idiopathic pul-
monary fibrosis, lenalidomide in multiple myeloma, and
nilotinib in chronic myeloid leukaemia, included more
patients than the mifamurtide trial; however, in each
case the prevalence of the orphan condition was higher
than that of osteosarcoma (≤3/10,000, 1.3/10,000 and
1.0/10,000, respectively).
Although this analysis has focused on patient numbers
and duration of follow-up as a measure of trial quality, a
number of other potential measures are available, in-
cluding the Jadad scoring system [13] and the criteria of
the Oxford Centre for Evidence-based Medicine [18]
and the Cochrane Collaboration [19]. Application of the
Jadad system to the studies included in this analysis con-
firmed that the trials had significant limitations with re-
spect to randomization or blinding, as discussed below.
Fig. 2 Cumulative duration of follow-up in relation to the reported prevalence of the orphan conditions. Prevalence data derived from the rele-
vant EMA Committee for Orphan Medicinal Products public summary of opinion for each treatment [3]. EMA, European Medicines Agency; MCL,
mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; OC, ovarian cancer; RCC, renal cell carcinoma; STS, soft
tissue sarcoma
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In addition to inadequate patient numbers and follow-
up, pivotal trials of orphan treatments may also be lim-
ited by the use of surrogate endpoints rather than clin-
ical survival-based endpoints. In the present study, five
of the 30 ATC category L treatments were excluded
from the review for this reason. Although desirable, the
use of survival-based clinical endpoints may make it dif-
ficult to demonstrate statistically significant treatment
effects in trials of orphan treatments where, as noted
above, patient numbers and duration of treatment may
be limited [7, 20]. Conversely, it may be easier to dem-
onstrate significant treatment effects on surrogate end-
points, but such endpoints are less likely to be acceptable
to regulators [7, 21]. The choice of endpoint therefore re-
flects a balance between the need for adequate statistical
power in the trial and the requirements of regulatory
authorities [7].
A further issue is the lack of randomization or blind-
ing, or both, in many pivotal trials of drugs for orphan
conditions. It is noteworthy that more than a third of
the trials reviewed in the present study were non-
randomized, and less than 40 % were appropriately ran-
domized or blinded. Indeed, the three trials with the
most extensive follow-up in terms of patient-years (mifa-
murtide in osteosarcoma, thalidomide in untreated mul-
tiple myeloma, and trabectedin in ovarian cancer) all
had randomized open-label designs. In many cases, the
lack of randomization may reflect the small number of
patients with the condition; there are also ethical consider-
ations relating to the use of placebos in life-threatening
conditions for which no alternative therapy is available for
use as a comparator.
In the present study, treatments were only eligible
for review if they had received EMA approval after 31
December 2006, in order to maximize the likelihood
that all reviewed treatments had been evaluated accord-
ing to similar criteria. The finding that methodological
issues relating to pivotal trials of the approved products
were similar to those reported by Joppi et al. in 2006 [4]
suggests that the criteria for evaluation of orphan treat-
ments have not become more stringent over time. A re-
cent study, which reviewed the EMA evaluations of 17
orphan drugs and 51 non-orphan drugs conducted dur-
ing 2009–2010, concluded that the regulatory standards
applied to orphan drugs were as rigorous as those ap-
plied to non-orphan drugs [22].
Conclusions
The results of this analysis show that 30 treatments be-
longing to ATC category L (antineoplastic and immu-
nomodulating agents) received an EMA marketing
authorization for 41 orphan indications between 31
December 2006 and 1 February 2014. Of the 37 indica-
tions for which clinical trial data were presented, 52 %
of the pivotal studies were Phase III trials and RCT
data were provided in 57 % of the pivotal studies. Be-
cause this analysis was restricted to ATC category L
products, and the prevalence of oncological orphan
diseases is often higher than that of many non-
oncological orphan diseases, the results may not be ap-
plicable to the latter situation.
This study shows that problems relating to low patient
numbers, or other methodological limitations, do not
necessarily preclude approval of an orphan product. The
pivotal clinical trial for mifamurtide in osteosarcoma
had the largest number of patient-years of follow-up
(4068 patient-years) of any of the reviewed treatments,
despite a small eligible patient population (0.5/10,000
persons); by contrast, the next largest study, of thalido-
mide in multiple myeloma, had 2906 patient-years of
follow-up in an eligible population of 1.2/10,000 persons.
Furthermore, each of the three treatments with the lon-
gest durations of follow-up were limited by a lack of
blinding or (in the case of the thalidomide and trabecte-
din trials) the use of suboptimal endpoints. Nevertheless,
each of these trials was considered adequate to support
approval of the treatment by the EMA.
The low prevalence of orphan diseases is an important
factor in the limited patient numbers and inadequate
follow-up in many of the clinical trials included in the
dossiers. Pooling of expertise through the establishment
of rare disease reference networks and patient registries
may improve this situation.
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